References
W Yeo WM Ho P Hui et al. (2004) ArticleTitleUse of lamivudine to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patients Breast Cancer Res Treat 88 209–215 Occurrence Handle10.1007/s10549-004-0725-1 Occurrence Handle1:CAS:528:DC%2BD2MXht1Kjt7s%3D Occurrence Handle15609123
MS Dai PF Wu RY Shyu et al. (2004) ArticleTitleHepatitis B virus reactivation in breast cancer patients undergoing cytotoxic chemotherapy and the role of preemptive lamivudine administration Liver Int 24 540–546 Occurrence Handle10.1111/j.1478-3231.2004.0964.x Occurrence Handle1:CAS:528:DC%2BD2MXmtVaitA%3D%3D Occurrence Handle15566502
W Yeo PK Chan HL Chan et al. (2001) ArticleTitleHepatitis B virus reactivation during cytotoxic chemotherapy-enhanced viral replication precedes overt hepatitis J Med Virol 65 473–477 Occurrence Handle10.1002/jmv.2060 Occurrence Handle1:STN:280:DC%2BD3MrkvFSrsw%3D%3D Occurrence Handle11596081
GK Lau YH Leung DY Fong et al. (2002) ArticleTitleHigh hepatitis B virus (HBV) DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantation Blood 99 2324–2330 Occurrence Handle10.1182/blood.V99.7.2324 Occurrence Handle1:CAS:528:DC%2BD38XisFGhsrg%3D Occurrence Handle11895763
S Zhong W Yeo C Schroder et al. (2004) ArticleTitleHigh hepatitis B virus (HBV) DNA viral load is an important risk factor for HBV reactivation in breast cancer patients undergoing cytotoxic chemotherapy J Viral Hepat 11 55–59 Occurrence Handle10.1046/j.1352-0504.2003.00467.x Occurrence Handle1:STN:280:DC%2BD2c%2FjvFyiuw%3D%3D Occurrence Handle14738558
MS Dai JJ Lu YC Chen et al. (2001) ArticleTitleReactivation of precore mutant hepatitis B virus in chemotherapy-treated patients Cancer 92 2927–2932 Occurrence Handle10.1002/1097-0142(20011201)92:11<2927::AID-CNCR10109>3.0.CO;2-W Occurrence Handle1:CAS:528:DC%2BD38Xms1w%3D Occurrence Handle11753968
GK Lau HH Yiu DY Fong et al. (2003) ArticleTitleEarly is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy Gastroenterology 125 1742–1749 Occurrence Handle1:CAS:528:DC%2BD2cXhtVOruw%3D%3D Occurrence Handle14724827
SY Ma GK Lau VC Cheng et al. (2003) ArticleTitleHepatitis B reactivation in patients positive for hepatitis B surface antigen undergoing autologous hematopoietic cell transplantation Leuk Lymphoma 44 1281–1285 Occurrence Handle10.1080/1042819031000083343 Occurrence Handle1:CAS:528:DC%2BD3sXisl2rsw%3D%3D Occurrence Handle12952220
DT Lau MF Khokhar E Doo et al. (2000) ArticleTitleLong-term therapy of chronic hepatitis B with lamivudine Hepatology 32 IssueID4 Pt 1 828–834 Occurrence Handle10.1053/jhep.2000.17912 Occurrence Handle1:CAS:528:DC%2BD3cXnslemsbY%3D Occurrence Handle11003630
F Perez-Roldan P Gonzalez-Carro MC Villafanez-Garcia (2005) ArticleTitleAdefovir dipivoxil for chemotherapy-induced activation of hepatitis B virus infection N Engl J Med 352 310–311 Occurrence Handle10.1056/NEJM200501203520324 Occurrence Handle1:CAS:528:DC%2BD2MXmvVeksQ%3D%3D Occurrence Handle15659742
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Dai, MS., Chao, TY. Lamivudine therapy in HBsAg-carrying breast cancer patients undergoing chemotherapy: prophylactic or preemptive?. Breast Cancer Res Treat 92, 95–96 (2005). https://doi.org/10.1007/s10549-005-1942-y
Issue Date:
DOI: https://doi.org/10.1007/s10549-005-1942-y